{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=standard+medication+label", "query": { "intervention": "standard medication label" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 493, "total_pages": 50, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=standard+medication+label&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T03:44:13.830Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02452918", "title": "A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acute Bacterial Skin and Skin Structure Infection" ], "interventions": [ { "name": "Oritavancin", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Medicines Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2015-09-29", "completion_date": "2016-07-05", "has_results": true, "last_update_posted_date": "2023-12-20", "last_synced_at": "2026-09-13T03:44:13.830Z", "location_count": 1, "location_summary": "Somers Point, New Jersey", "locations": [ { "city": "Somers Point", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02452918" }, { "nct_id": "NCT02082522", "title": "Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hilar Cholangiocarcinoma" ], "interventions": [ { "name": "Photodynamic therapy-Photofrin", "type": "DRUG" }, { "name": "Stenting procedure", "type": "PROCEDURE" }, { "name": "Chemotherapy regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Concordia Laboratories Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2014-11-12", "completion_date": "2017-01-12", "has_results": true, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-09-13T03:44:13.830Z", "location_count": 18, "location_summary": "Goodyear, Arizona • Scottsdale, Arizona • Los Angeles, California + 14 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02082522" }, { "nct_id": "NCT03699319", "title": "CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "CPI 613", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "5-flurouracil", "type": "DRUG" }, { "name": "Folinic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Bajor, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 49, "start_date": "2018-12-07", "completion_date": "2024-09-23", "has_results": false, "last_update_posted_date": "2025-01-23", "last_synced_at": "2026-09-13T03:44:13.830Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03699319" }, { "nct_id": "NCT02286492", "title": "Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "TAS-102", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2024-09-05", "last_synced_at": "2026-09-13T03:44:13.830Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Fresno, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Gilroy", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02286492" }, { "nct_id": "NCT02101385", "title": "Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Neoplasm of Breast", "Breast Cancer" ], "interventions": [ { "name": "Genomically Directed Monotherapy", "type": "DRUG" }, { "name": "Observation/Standard Therapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bryan Schneider, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 193, "start_date": "2014-04-03", "completion_date": "2022-09-09", "has_results": true, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-09-13T03:44:13.830Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02101385" }, { "nct_id": "NCT02973789", "title": "Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Nonsmall Cell Lung Cancer", "NSCLC" ], "interventions": [ { "name": "NovoTTF-200T", "type": "DEVICE" }, { "name": "Immune checkpoint inhibitors or docetaxel", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "NovoCure GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 291, "start_date": "2016-12", "completion_date": "2024-10-09", "has_results": true, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-09-13T03:44:13.830Z", "location_count": 73, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 59 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02973789" }, { "nct_id": "NCT00658359", "title": "Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "Cyclosporine", "type": "DRUG" }, { "name": "CP-690,550", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 178, "start_date": "2008-08", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2018-02-23", "last_synced_at": "2026-09-13T03:44:13.830Z", "location_count": 37, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00658359" }, { "nct_id": "NCT02327169", "title": "A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Nonhematologic Malignancies" ], "interventions": [ { "name": "MLN2480", "type": "DRUG" }, { "name": "MLN0128", "type": "DRUG" }, { "name": "Alisertib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2015-01-14", "completion_date": "2018-07-02", "has_results": true, "last_update_posted_date": "2020-02-25", "last_synced_at": "2026-09-13T03:44:13.830Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02327169" }, { "nct_id": "NCT04093167", "title": "Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Canadian Cancer Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2020-05-26", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-13T03:44:13.830Z", "location_count": 2, "location_summary": "Chicago, Illinois • Baltimore, Maryland", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04093167" }, { "nct_id": "NCT03635957", "title": "Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Gout" ], "interventions": [ { "name": "Pegloticase", "type": "BIOLOGICAL" }, { "name": "Methotrexate (MTX)", "type": "DRUG" }, { "name": "Standard Gout Flare Prophylaxis", "type": "DRUG" }, { "name": "Infusion Reaction (IR) Prophylaxis", "type": "DRUG" }, { "name": "Folic Acid", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 14, "start_date": "2018-09-26", "completion_date": "2020-10-26", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-09-13T03:44:13.830Z", "location_count": 6, "location_summary": "Anchorage, Alaska • Glendale, Arizona • Mesa, Arizona + 3 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "DeLand", "state": "Florida" }, { "city": "Bothell", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03635957" } ] }